First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Scholar Rock Holding Corporation (SRRK): the developments shaping its investment case

    Follow the evidence affecting Scholar Rock Holding Corporation's valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Scholar Rock Holding Corporation · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-14 · 4 reports
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    Channel: Direct commercialization of a novel therapeutic, market entry into a high-value rare disease segment.
    Bullish· 1-3m
    2026-09-14 · 4 reports
    FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA
    Channel: Direct product approval and commercialization opportunity. This is a significant milestone for a biotech company, transitioning from R&D to revenue generation.
    Bullish· 1-3m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-08-06multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.
    2026-08-06share_countBullishPrimary equity issuance increases diluted share count.

    Event impact log

    8 events mapped to SRRK since 2026-09-12. Evidence through 2026-09-14.

    DateEventChannelDirectionHorizonImpact
    2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyDirect commercialization of a novel therapeutic, market entry into a high-value rare disease segment.Bullish1-3m0.90
    2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMADirect product approval and commercialization opportunity. This is a significant milestone for a biotech company, transitioning from R&D to revenue generation.Bullish1-3m0.90
    2026-09-13FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA TherapyDirect regulatory approval for lead product, enabling market entry and revenue generation.Bullish1-3m0.90
    2026-09-13FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyDirect revenue generation from drug sales, transition to commercial-stage biopharma.Bullish1-3m0.90
    2026-09-12FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMADirect market entry and revenue generation for lead product.Bullish1-3m0.90
    2026-09-12FDA Approves Isembyld for Spinal Muscular AtrophyDirect revenue generation from drug sales, increased market valuation due to successful R&D, potential for future pipeline validation.Bullish1-3m0.90
    2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapyDirect product approval leading to market entry and revenue generation.Bullish1-5y0.90
    2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophyDirect regulatory approval leading to commercialization, shifting from R&D to sales-driven operations.Bullish1-3m0.90

    Continue this research

    Build your Scholar Rock Holding Corporation investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the SRRK entity page →

    Research Scholar Rock Holding Corporation · $399/mo